386 related articles for article (PubMed ID: 17105223)
21. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase.
Shen LJ; Beloussow K; Shen WC
Cancer Lett; 2006 Jan; 231(1):30-5. PubMed ID: 16356828
[TBL] [Abstract][Full Text] [Related]
22. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
23. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
24. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.
Kearney PL; Bhatia M; Jones NG; Yuan L; Glascock MC; Catchings KL; Yamada M; Thompson PR
Biochemistry; 2005 Aug; 44(31):10570-82. PubMed ID: 16060666
[TBL] [Abstract][Full Text] [Related]
25. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
26. Aspergillus nidulans thermostable arginine deiminase-Dextran conjugates with enhanced molecular stability, proteolytic resistance, pharmacokinetic properties and anticancer activity.
El-Sayed ASA; Shindia AA; Zeid AAA; Yassin AM; Sitohy MZ; Sitohy B
Enzyme Microb Technol; 2019 Dec; 131():109432. PubMed ID: 31615671
[TBL] [Abstract][Full Text] [Related]
27. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
[TBL] [Abstract][Full Text] [Related]
28. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
29. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Kim JH; Kim JH; Yu YS; Kim DH; Min BH; Kim KW
Oncol Rep; 2007 Dec; 18(6):1373-7. PubMed ID: 17982619
[TBL] [Abstract][Full Text] [Related]
31. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
Zhao H; Peng P; Longley C; Zhang Y; Borowski V; Mehlig M; Reddy P; Xia J; Borchard G; Lipman J; Benimetskaya L; Stein CA
J Control Release; 2007 Jun; 119(2):143-52. PubMed ID: 17397960
[TBL] [Abstract][Full Text] [Related]
32. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
33. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
34. Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.
Felix AM; Lu YA; Campbell RM
Int J Pept Protein Res; 1995; 46(3-4):253-64. PubMed ID: 8537179
[TBL] [Abstract][Full Text] [Related]
35. Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics.
Kronman C; Cohen O; Mazor O; Ordentlich A; Raveh L; Velan B; Shafferman A
Chem Biol Interact; 2010 Sep; 187(1-3):253-8. PubMed ID: 20005217
[TBL] [Abstract][Full Text] [Related]
36. A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Zhu L; Verma R; Roccatano D; Ni Y; Sun ZH; Schwaneberg U
Chembiochem; 2010 Nov; 11(16):2294-301. PubMed ID: 20954230
[TBL] [Abstract][Full Text] [Related]
37. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
38. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.
Miyazaki K; Takaku H; Umeda M; Fujita T; Huang WD; Kimura T; Yamashita J; Horio T
Cancer Res; 1990 Aug; 50(15):4522-7. PubMed ID: 2164440
[TBL] [Abstract][Full Text] [Related]
39. Amino Acids Sequence-based Analysis of Arginine Deiminase from Different Prokaryotic Organisms: An In Silico Approach.
Abdollahi S; Morowvat MH; Savardashtaki A; Irajie C; Najafipour S; Zarei M; Ghasemi Y
Recent Pat Biotechnol; 2020; 14(3):235-246. PubMed ID: 32208128
[TBL] [Abstract][Full Text] [Related]
40. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2.
Digilio G; Barbero L; Bracco C; Corpillo D; Esposito P; Piquet G; Traversa S; Aime S
J Am Chem Soc; 2003 Mar; 125(12):3458-70. PubMed ID: 12643708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
